<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500123</url>
  </required_header>
  <id_info>
    <org_study_id>HR 9556</org_study_id>
    <nct_id>NCT00500123</nct_id>
  </id_info>
  <brief_title>Alpha-1 Coded Testing(ACT) Study</brief_title>
  <acronym>ACT</acronym>
  <official_title>Alpha-1 Coded Testing(ACT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes
      of individuals at risk for alpha-1 antitrypsin deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established
      testing indications. All genetic tests have risks and possible benefits. The ACT study
      evaluates the population demographics, reasons for testing, and outcomes through a
      confidential testing program. Co-morbidities of alpha-1 antitrypsin deficiency other than
      lung and liver disease are being investigated. Concerns about genetic confidentiality are
      lessened in this study by a coded testing procedure that returns results through the mail to
      study participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Anticipated">January 2050</completion_date>
  <primary_completion_date type="Anticipated">January 2050</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>50 Years</target_duration>
  <primary_outcome>
    <measure>Structured questionnaire responses on the risks and benefits of testing.</measure>
    <time_frame>Before and after alpha-1 antitrypsin testing</time_frame>
    <description>Rotating questionnaires assess the clinical course and co-morbidities associated with different genotypes of alpha-1 antitrypsin deficiency.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Alpha-1 Antitrypsin Genotype</intervention_name>
    <description>Home fingerstick testing for alpha-1 antitrypsin genotype</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A blood card is mailed to the participants home. The provide lancet is used for fingerstick
      collection of sufficient bloodspots to genotype for alpha-1 antitrypsin (AAT) deficiency
      alleles and to estimate an AAT level.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals choosing to test at home for alpha-1 antitrypsin deficiency.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of
             symptoms or family genetic risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlie Strange, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlie Strange, M.D.</last_name>
    <phone>843-792-0260</phone>
    <email>alphaone@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlie Strange, MD</last_name>
    <phone>843-792-3174</phone>
    <email>strangec@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina. Division of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alphaoneregistry.org</url>
    <description>Alpha-1 Coded Testing Link</description>
  </link>
  <reference>
    <citation>Coors ME, Moseley R, McGorray S. Informed consent process in Alpha-1 testing of at-risk children: views of parents and adults tested as children. COPD. 2011 Feb;8(1):30-8. doi: 10.3109/15412555.2010.541958.</citation>
    <PMID>21299476</PMID>
  </reference>
  <reference>
    <citation>Holm KE, Borson S, Sandhaus RA, Ford DW, Strange C, Bowler RP, Make BJ, Wamboldt FS. Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD. 2013 Apr;10(2):226-34. doi: 10.3109/15412555.2012.719049.</citation>
    <PMID>23547634</PMID>
  </reference>
  <reference>
    <citation>Stoller JK, Strange C, Schwarz L, Kallstrom TJ, Chatburn RL. Detection of alpha-1 antitrypsin deficiency by respiratory therapists: experience with an educational program. Respir Care. 2014 May;59(5):667-72. doi: 10.4187/respcare.02817. Epub 2013 Oct 8.</citation>
    <PMID>24106322</PMID>
  </reference>
  <results_reference>
    <citation>Strange C, Dickson R, Carter C, Carpenter MJ, Holladay B, Lundquist R, Brantly ML. Genetic testing for alpha1-antitrypsin deficiency. Genet Med. 2004 Jul-Aug;6(4):204-10.</citation>
    <PMID>15266208</PMID>
  </results_reference>
  <results_reference>
    <citation>Strange C, Moseley MA, Jones Y, Schwarz L, Xie L, Brantly ML. Genetic testing of minors for alpha1-antitrypsin deficiency. Arch Pediatr Adolesc Med. 2006 May;160(5):531-4.</citation>
    <PMID>16651497</PMID>
  </results_reference>
  <results_reference>
    <citation>Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, Moseley MA, Gilbert GE. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med. 2007 Feb;33(1):22-8.</citation>
    <PMID>17291167</PMID>
  </results_reference>
  <results_reference>
    <citation>McGee D, Strange C, McClure R, Schwarz L, Erven M. The Alpha-1 Association Genetic Counseling Program: an innovative approach to service. J Genet Couns. 2011 Aug;20(4):330-6. doi: 10.1007/s10897-011-9355-z. Epub 2011 Mar 19.</citation>
    <PMID>21424325</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Charlie Strange</investigator_full_name>
    <investigator_title>Professor of Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>alpha-1</keyword>
  <keyword>antitrypsin</keyword>
  <keyword>AAT</keyword>
  <keyword>genetic testing</keyword>
  <keyword>alpha-1 antitrypsin deficiency</keyword>
  <keyword>AATD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing is encouraged by MUSC coordinator contact</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

